APA (7th ed.) Citation

W, P., L, B., S, G., M, J., L, M., E, S., . . . P, B. (2020). Inhibiting the mitochondrial pyruvate carrier does not ameliorate synucleinopathy in the absence of inflammation or metabolic deficits. Free neuropathology, 1, 33. https://doi.org/10.17879/freeneuropathology-2020-3049

Chicago Style (17th ed.) Citation

W, Peelaerts, et al. "Inhibiting the Mitochondrial Pyruvate Carrier Does Not Ameliorate Synucleinopathy in the Absence of Inflammation or Metabolic Deficits." Free Neuropathology 1 (2020): 33. https://doi.org/10.17879/freeneuropathology-2020-3049.

MLA (9th ed.) Citation

W, Peelaerts, et al. "Inhibiting the Mitochondrial Pyruvate Carrier Does Not Ameliorate Synucleinopathy in the Absence of Inflammation or Metabolic Deficits." Free Neuropathology, vol. 1, 2020, p. 33, https://doi.org/10.17879/freeneuropathology-2020-3049.